A placebo-controlled comparability study to compare two presentations of cagrilintide for weight management in participants with overweight or obesity

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524249-29-00

Enrollment

171

Registered

2026-07-20

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Participants with overweight or obesity

Brief summary

Relative change in body weight from baseline (week 0) to end of treatment (week 26)

Detailed description

Number of treatment emergent adverse events (TEAEs) from baseline (week 0) to end of study (week 33), Number of treatment emergent serious adverse events (TESAEs) from baseline (week 0) to end of study (week 33)

Interventions

DRUGcagrilintide D 10137

DRUGPlacebo

DRUGcagrilintide D 10138

DRUGcagrilintide

DRUGcagrilintide D 10135

DRUGcagrilintide D 10136

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Relative change in body weight from baseline (week 0) to end of treatment (week 26)	—

Secondary

Measure	Time frame
Number of treatment emergent adverse events (TEAEs) from baseline (week 0) to end of study (week 33), Number of treatment emergent serious adverse events (TESAEs) from baseline (week 0) to end of study (week 33)	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 22, 2026